Valuation: GENFIT

Market Cap 705M 824M 659M 604M 1.14B 78.84B 1.16B 7.81B 3.04B 39.6B 3.09B 3.03B 131B P/E 2026 *
36.4x
P/E 2027 * 93.6x
Enterprise Value 654M 764M 611M 561M 1.05B 73.12B 1.07B 7.25B 2.82B 36.73B 2.87B 2.81B 121B EV / Sales 2026 *
6.53x
EV / Sales 2027 * 5.15x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day+5.28%
1 week+12.89%
Current month+2.43%
1 month+12.01%
3 months+71.57%
6 months+91.98%
Current year+173.78%
1 week 12.94
Extreme 12.94
14.36
1 month 12.72
Extreme 12.72
14.86
Current year 5.08
Extreme 5.075
14.86
1 year 3.01
Extreme 3.006
14.86
3 years 2.8
Extreme 2.8
14.86
5 years 2.74
Extreme 2.74
14.86
10 years 2.74
Extreme 2.74
33.76
Manager TitleAgeSince
Chief Executive Officer 58 15/09/2019
Director of Finance/CFO 52 21/04/2021
Chief Tech/Sci/R&D Officer - 26/11/2025
Director TitleAgeSince
Chairman 70 15/06/2017
Director/Board Member 54 14/09/1999
Director/Board Member 58 15/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
+5.28%+12.89% - - 840M
+1.14%+3.46%+4.57%+24.14% 50.5B
-1.36%+3.15%+479.46%+614.84% 46.01B
-2.04%+2.82%+18.13%+91.23% 42.85B
+2.72%+5.93%+33.12%+19.66% 41.03B
0.00%-3.91%+17.87%+47.98% 32.02B
+0.72%+2.62%+32.57%+145.37% 16.98B
-1.85%-0.25% - - 17.05B
+3.06%+4.63%+7.40%+35.00% 14.3B
+0.50%+2.49%+83.90%+46.53% 13.84B
Average +0.82%+2.01%+84.63%+128.09% 30.51B
Weighted average by Cap. +0.20%+2.37%+104.14%+152.88%

Financials

2026 *2027 *
Net sales 100M 117M 93.63M 85.85M 161M 11.2B 164M 1.11B 432M 5.62B 439M 430M 18.61B 124M 145M 116M 106M 200M 13.86B 204M 1.37B 535M 6.96B 544M 532M 23.04B
Net income 22.88M 26.73M 21.38M 19.6M 36.84M 2.56B 37.56M 253M 98.74M 1.28B 100M 98.15M 4.25B 6.8M 7.95M 6.35M 5.83M 10.95M 760M 11.16M 75.32M 29.35M 382M 29.83M 29.17M 1.26B
Net Debt -51.12M -59.73M -47.77M -43.8M -82.32M -5.71B -83.92M -566M -221M -2.87B -224M -219M -9.49B -66.17M -77.32M -61.83M -56.7M -107M -7.4B -109M -733M -286M -3.71B -290M -284M -12.29B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change
20/08/26 €14.36 +5.28%
19/08/26 €13.64 -0.73%
18/08/26 €13.74 +6.18%
17/08/26 €12.94 -2.85%
14/08/26 €13.32 +2.46%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.10EUR
Average target price
15.90EUR
Spread / Average Target
+12.77%

Quarterly revenue - Rate of surprise